SBIR Phase II: Reversed Micellar Fractionation of Recombinant-DNA Therapeutic Protein Intermediates

SBIR II 期：重组 DNA 治疗性蛋白质中间体的反胶束分级分离

• 批准号: 9313977
• 负责人: Trevor Castor
• 金额: $ 28.14万
• 依托单位: Aphios Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-10-01 至 1998-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9313977&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Reversed; Micellar

9313977 Castor Reversed micelles hold much promise as a means of carrying out selective liquid-liquid extraction of proteins from solution mixtures such that the desired protein is obtained in a purer and more concentrated form than the original feed. Reversed micellar-organic (RM-ORG) phase separation could have significant utility in the primary purification or initial fractionation of biosynthetic protein production processes. The continuous flow RM-ORG process developed during Phase I was designed to displace conventional low resolution chromatographic purification processes which cause losses in yield and increased manufacturing costs. During Phase II, process stream parameters such as surfactant concentration and aqueous stream pH are to be optimized. These parameters play key roles in determining protein solubilization in reversed micelles. A continuous flow RM-ORG prototype is to be designed, constructed, and tested. Based on this information, an economic analysis of the prototype is to be performed.

9313977 Castor Reversed Micelles作为从溶液混合物中进行蛋白质的选择性液-液萃取的方法，具有很大的前景，这样可以获得比原始饲料更纯和更浓缩形式的所需蛋白质。 反胶束-有机相分离在生物合成蛋白质生产过程的初级纯化或初始分级中具有重要的实用性。 在第I阶段开发的连续流RM-ORG工艺旨在取代导致产率损失和生产成本增加的传统低分辨率色谱纯化工艺。 在第二阶段，工艺流参数，如表面活性剂浓度和水流pH值进行优化。 这些参数在确定蛋白质在反胶束中的增溶作用中起着关键作用。 一个连续流RM-ORG原型的设计，建造和测试。 根据这些信息，将对原型进行经济分析。